Cubital Tunnel Syndrome Market Research Report – Global Forecast till 2023

Report / Search Code: MRFR/HC/3210-HCRR  Publish Date: January, 2019

Description:

Cubital Tunnel Syndrome Market Research Report: By Cause (Injury, Noncancerous Fatty Tumor, Bone Tumor, Inflammation), Treatment (Diagnosis (MRI, X-Ray), Therapy (Non-Operative, Operative)), End User (Hospital, Retail Pharmacy) - Global Forecast Till 2023

Market Scenario:

Cubital tunnel syndrome is a condition of increased pressure on the ulnar nerve in the elbow. The ulnar nerve controls muscles and feeling in the hand. Furthermore, it can be caused by direct pressure, stretching, or decreased blood flow to the ulnar nerve. According to the WHO (2014), the incidence of carpal tunnel syndrome is >3 new cases per 1000 persons every year. Women are 3-4 times more susceptible than men. Increasing prevalence of the cubital tunnel syndrome is the major driving factor for the growth of the market. Moreover, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, geriatric population is more likely to suffer from this disease; According to the Aging World in 2015, 562 million (or 8.0 %) were aged 65 and over across the globe, this has increased the prevalence of the diseases and contributed to the growth of the market. However, lack of awareness among people and high cost of surgeries may restrain the growth of the market.

The global cubital tunnel syndrome market is expected to grow at a CAGR of 5.6% during forecast period 2017-2023.

Intended Audience

- Biotechnological institutes
- Pharmaceutical companies
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories

Figure 1:- Global cubital tunnel syndrome market share, by region (%)
Sources: WHO, annual reports, press release, white paper, and company presentation

**Segmentation**

The global cubital tunnel syndrome market is segmented on the basis of causes, treatment, and end users.

On the basis of causes, the market is segmented into injury, noncancerous fatty tumors, bone tumors, inflammation, and others.

On the basis of treatment, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into nerve compression tests, X-ray, electrodiagnostic studies, MRI, and others. The therapy is further segmented into non-operative, and operative. The non-operative is further classified into NSAIDs and steroids.

On the basis of end users, the market is segmented into hospital, retail pharmacy, and other.

**Regional Analysis**

The Americas dominates the global cubital tunnel syndrome market owing to large patient population. Additionally, increasing geriatric population, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the market in America. According to the Population Reference Bureau, the number of Americans ages 65 and over is projected to be more than double from 46 million in 2016 to over 98 million by 2060. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest cubital tunnel syndrome market, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development projected to drive the market in Europe.

Asia Pacific is the fastest growing region in the global market due to the presence of a increasing patient population, continuously developing economies, and increasing need for the better treatment. According to the WHO report published in 2015, Asia’s elderly population is projected to reach nearly 923 million by 2050.

Whereas, the Middle East & Africa owns the least share of the global cubital tunnel syndrome market due to the presence of poor economy, especially, in Africa region. The market of this region is dominated by the Middle East due to well-developed healthcare sector and huge healthcare expenditure.

**Research Methodology**
Key players in global cubital tunnel syndrome market

The major key players in the global cubital tunnel syndrome market: Eli Lily and Company (US), GlaxoSmithKline PLC (UK), Pfizer Inc., Depomed Inc., Novartis International AG (Switzerland), Johnson & Johnson Services Inc. (US), Bristol-Myers Squibb and Company (US), Sanofi S.A. (France), Debiopharm Group (Switzerland), Baxter Healthcare Corporation (US), Biogen Idec Inc. (US), Amneal Pharmaceuticals LLC. (US), Amgen, Inc. (US)
Chapter 6. Global Cubital Tunnel Syndrome Market, by Causes
6.1 Introduction
6.2 Injury
Market Estimates & Forecast, 2017 – 2023
6.3 Noncancerous Fatty Tumors
Market Estimates & Forecast, 2017 – 2023
6.4 Bone Tumors
Market Estimates & Forecast, 2017 – 2023
6.5 Inflammation
Market Estimates & Forecast, 2017 – 2023

Chapter 7. Global Cubital Tunnel Syndrome Market, by Treatment
7.1 Introduction
7.2 Diagnosis
Market Estimates & Forecast, 2017 – 2023
7.2.1 Nerve Compression Tests
7.2.2 X-Ray
7.2.3 Electrodiagnostic Studies
7.2.4 MRI
7.2.5 Others
7.3 Therapy
Market Estimates & Forecast, 2017 – 2023
7.3.1 Nonoperative
7.3.1.1 NSAIDs
7.3.1.2 Steroids
7.3.2 Operative

Chapter 8 Global Cubital Tunnel Syndrome Market, by End User
8.1 Introduction
8.2 Hospitals
Market Estimates & Forecast, 2017 – 2023
8.3 Retail Pharmacy
Market Estimates & Forecast, 2017 – 2023
8.4 Others

Chapter 9. Global Cubital Tunnel Syndrome Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles
11.1 Novartis AG
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Eli Lilly and Company
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 GlaxoSmithKline PLC
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Pfizer Inc.
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Sanofi S.A.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Johnson & Johnson Services Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Bristol-Myers Squibb and Company
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Cubital Tunnel Syndrome Industry Synopsis, 2017 – 2023
Table 2 Global Cubital Tunnel Syndrome Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Cubital Tunnel Syndrome Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Cubital Tunnel Syndrome Market by Causes, 2017 – 2023, (USD Million)
Table 5 Global Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 6 Global Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 7 North America Cubital Tunnel Syndrome Market by Causes, 2017 – 2023, (USD Million)
Table 8 North America Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 9 North America Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 10 US Market by Causes, 2017 – 2023, (USD Million)
Table 11 US Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 12 US Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Market by Causes, 2017 – 2023, (USD Million)
Table 14 Canada Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 15 Canada Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Market by Causes, 2017 – 2023, (USD Million)
Table 17 South America Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 18 South America Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Market by Causes, 2017 – 2023, (USD Million)
Table 20 Europe Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 21 Europe Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Market by Causes, 2017 – 2023, (USD Million)
Table 23 Western Europe Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 24 Western Europe Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Market by Causes, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Eastern Europe Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 28 Asia Pacific Market by Causes, 2017 – 2023, (USD Million)
Table 29 Asia Pacific Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 30 Asia Pacific Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)
Table 31 Middle East & Africa Market by Causes, 2017 – 2023, (USD Million)
Table 32 Middle East & Africa Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)
Table 33 Middle East & Africa Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Cubital Tunnel Syndrome Market
Figure 3 Segmentation Market Dynamics for Global Cubital Tunnel Syndrome Market
Figure 4 Global Cubital Tunnel Syndrome market Share, by Causes 2016
Figure 5 Global Cubital Tunnel Syndrome market Share, by Treatment 2016
Figure 6 Global Cubital Tunnel Syndrome Market Share, by End Users, 2016
Figure 7 Global Cubital Tunnel Syndrome Market Share, by Region, 2016
Figure 8 North America Cubital Tunnel Syndrome Market Share, by Country, 2016
Figure 9 Europe Cubital Tunnel Syndrome Market Share, by Country, 2016
Figure 10 Asia Pacific Cubital Tunnel Syndrome Market Share, by Country, 2016
Figure 11 Middle East & Africa Cubital Tunnel Syndrome Market Share, by Country, 2016
Figure 12 Global Cubital Tunnel Syndrome Market: Company Share Analysis, 2016 (%)
Figure 13 Novartis AG: Key Financials
Figure 14 Novartis AG: Segmental Revenue
Figure 15 Novartis AG: Geographical Revenue
Figure 16 Eli Lilly and Company: Key Financials
Figure 17 Eli Lilly and Company: Segmental Revenue
Figure 18 Eli Lilly and Company: Geographical Revenue
Figure 19 GlaxoSmithKline PLC: Key Financials
Figure 20 GlaxoSmithKline PLC: Segmental Revenue
Figure 21 GlaxoSmithKline PLC: Geographical Revenue
Figure 22 Pfizer Inc.: Key Financials
Figure 23 Pfizer Inc.: Segmental Revenue
Figure 24 Pfizer Inc.: Geographical Revenue
Figure 25 Sanofi: Key Financials
Figure 26 Sanofi S.A.: Segmental Revenue
Figure 27 Sanofi S.A.: Geographical Revenue
Figure 28 Johnson & Johnson Services Inc.: Key Financials
Figure 29 Johnson & Johnson Services Inc.: Segmental Revenue
Figure 30 Johnson & Johnson Services Inc.: Geographical Revenue
Figure 31 Bristol-Myers Squibb and Company: Key Financials
Figure 32 Bristol-Myers Squibb and Company: Segmental Revenue
Figure 33 Bristol-Myers Squibb and Company: Geographical Revenue